Evidence map›Paper›PMID 40489668›Full record

Trial reportRheumatology (Oxford, England)2025

Automated detection of spinal bone marrow oedema in axial spondyloarthritis: training and validation using two large phase 3 trial datasets.

Amir Jamaludin, Rhydian Windsor, Sarim Ather, Timor Kadir, Andrew Zisserman, Juergen Braun, Lianne S Gensler, Mikkel Østergaard, Denis Poddubnyy, Thibaud Coroller and 4 more

2 registry-linked trialsAbstract readClinical Trial, Phase IIIRandomized Controlled TrialValidation Study
In one paragraph

Trial report in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01358175 phase3completednot on this map

A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the 16 Week Efficacy and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis

TypeinterventionalSponsorNovartis PharmaceuticalsRan2011 to 2014Enrolled371ConditionsAnkylosing SpondylitisArmsSecukinumab (75 mg), Secukinumab (150 mg), Placebo
NCT02696031 phase3completednot on this map

A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs

TypeinterventionalSponsorNovartis PharmaceuticalsRan2016 to 2021Enrolled555ConditionsNon-radiographic SpondyloarthritisArmsSecukinumab, Placebo
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. External validation of SpineNetv2 deep learning system for automated lumbar spine MRI analysis: A multi-pathology diagnostic agreement study.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Amir JamaludinVisual Geometry Group, Department of Engineering Science, University of Oxford, Oxford, UK.
Rhydian WindsorVisual Geometry Group, Department of Engineering Science, University of Oxford, Oxford, UK.
Sarim AtherOxford University Hospitals NHS Foundation Trust, Oxford, UK.
Timor KadirSelka Health, Oxforrd, UK.
Andrew ZissermanVisual Geometry Group, Department of Engineering Science, University of Oxford, Oxford, UK.
Juergen BraunRheuma Praxis Berlin, Berlin, Germany.
Lianne S GenslerDivision of Rheumatology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-6314-5336
Mikkel ØstergaardCopenhagen Centre for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark.ORCID 0000-0003-3690-467X
Denis PoddubnyyDivision of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Canada.ORCID 0000-0002-4537-6015
Thibaud CorollerNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Brian PorterNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Gregory LigozioNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Aimee ReadieNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Pedro M MachadoDepartment of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK.ORCID 0000-0002-8411-7972

Funding

Novartis
6 · The paper itself

Abstract

objectiveTo evaluate the performance of machine learning (ML) models for the automated scoring of spinal MRI bone marrow oedema (BMO) in patients with axial spondyloarthritis (axSpA) and compare them with expert scoring.

methodsML algorithms using SpineNet software were trained and validated on 3483 spinal MRIs from 686 axSpA patients across two clinical trial datasets. The scoring pipeline involved (i) detection and labelling of vertebral bodies and (ii) classification of vertebral units for the presence or absence of BMO. Two models were tested: Model 1, without manual segmentation, and Model 2, incorporating an intermediate manual segmentation step. Model outputs were compared with those of human experts using kappa statistics, balanced accuracy, sensitivity, specificity and AUC.

resultsBoth models performed comparably to expert readers, regarding presence vs absence of BMO. Model 1 outperformed Model 2, with an AUC of 0.94 (vs 0.88), accuracy of 75.8% (vs 70.5%) and kappa of 0.50 (vs 0.31) using absolute reader consensus scoring as the external reference; this performance was similar to the expert inter-reader accuracy of 76.8% and kappa of 0.47 in a radiographic axSpA dataset. In a non-radiographic axSpA dataset, Model 1 achieved an AUC of 0.97 (vs 0.91 for Model 2), accuracy of 74.6% (vs 70%) and kappa of 0.52 (vs 0.27), comparable to the expert inter-reader accuracy of 74.2% and kappa of 0.46.

conclusionML software shows potential for automated MRI BMO assessment in axSpA, offering benefits such as improved consistency, reduced labour costs and minimized inter- and intra-reader variability.

trial registrationClinicaltrials.gov, http://clinicaltrials.gov, MEASURE 1 study (NCT01358175); PREVENT study (NCT02696031).

Indexed as

Axial SpondyloarthritisBone Marrow DiseasesEdemaMachine LearningMagnetic Resonance ImagingAdultAlgorithmsFemaleHumansMaleMiddle AgedSensitivity and SpecificitySpineankylosing spondylitisartificial intelligenceaxial spondyloarthritisbone marrow oedemainflammationmachine learningMRIosteitis

Identifiers

PMID40489668
PMCPMC12494195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.